ARHGAP40 Inhibitors
ARHGAP40 inhibitors typically act by modulating the activity of GTPases and their associated pathways. Several inhibitors, such as Y-27632, H1152, GSK429286A, and RKI-1447, target the Rho/ROCK pathway. Given that ARHGAP40 is a RhoGAP, these inhibitors can indirectly reduce its functional activity by suppressing the Rho/ROCK pathway. The inhibition of this pathway decreases the number of active GTPases, thereby reducing the opportunity for ARHGAP40 to exert its GAP activity.
Other inhibitors, including NSC23766, ML141, EHT 1864, and ZCL278, target specific GTPases, such as Rac1 and Cdc42. These GTPases are known to interact with ARHGAP40, and their inhibition can reduce the pool of active GTPases with which ARHGAP40 can interact, leading to decreased ARHGAP40 function. Additional inhibitors, such as IPA-3, SecinH3, and ITX3, disrupt downstream signaling or manipulate the activities of other guanine nucleotide exchange factors (GEFs). IPA-3, for instance, inhibits PAK1, a downstream effector of Rho GTPases, thereby disrupting the signaling downstream of GTPase activation that ARHGAP40 is involved in. SecinH3 and ITX3 inhibit Cytohesin and Trio, respectively, both of which are GEFs for different types of GTPases. By reducing the pool of active GTPases through the inhibition of these GEFs, these chemicals can indirectly inhibit ARHGAP40. The case of Tozasertib is a bit different: as an inhibitor of Aurora A and B kinases, which play a role in cell cycle progression, its effect on ARHGAP40 is less direct but may potentially alter its functional activity during cell division.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $104.00 $364.00 | 7 | |
H1152 is a more potent and selective inhibitor of ROCK than Y-27632. It can indirectly inhibit ARHGAP40 by suppressing the Rho/ROCK pathway, thereby reducing the functional activity of ARHGAP40. | ||||||
IPA 3 | 42521-82-4 | sc-204016 sc-204016A | 5 mg 50 mg | $94.00 $458.00 | 6 | |
IPA-3 is a selective inhibitor of PAK1, a downstream effector of Rho GTPases. Inhibiting PAK1 can indirectly inhibit ARHGAP40 by disrupting the signaling downstream of GTPase activation. | ||||||
GSK 429286 | 864082-47-3 | sc-361200 sc-361200B sc-361200A | 1 mg 5 mg 10 mg | $40.00 $125.00 $235.00 | ||
GSK429286A is a selective inhibitor of ROCK1 and ROCK2. It can indirectly inhibit ARHGAP40 by suppressing the Rho/ROCK pathway. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3 is an inhibitor of Cytohesin, a guanine nucleotide exchange factor (GEF) for ARF GTPases. By inhibiting Cytohesin, SecinH3 can indirectly inhibit the functional activity of ARHGAP40 by reducing the pool of active GTPases. | ||||||
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | $213.00 $889.00 | 12 | |
EHT 1864 is a Rac GTPase inhibitor. By inhibiting Rac, EHT 1864 can indirectly inhibit ARHGAP40 as it reduces the number of active GTPases that ARHGAP40 can interact with. | ||||||
ITX 3 | 347323-96-0 | sc-295214 sc-295214A | 10 mg 50 mg | $145.00 $615.00 | ||
ITX3 is a selective inhibitor of Trio, a Rho guanine nucleotide exchange factor (GEF). By inhibiting Trio, ITX3 can indirectly inhibit the functional activity of ARHGAP40 by reducing the pool of active GTPases. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
ZCL278 is a direct inhibitor of Cdc42, which can indirectly inhibit ARHGAP40 by reducing the pool of active GTPases that ARHGAP40 can interact with. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
Tozasertib is a potent inhibitor of Aurora A and B kinases. Given the role of these kinases in cell cycle progression, their inhibition can indirectly affect ARHGAP40, potentially altering its functional activity during cell division. | ||||||
RKI-1447 | 1342278-01-6 | sc-472590 | 1 mg | $330.00 | ||
RKI-1447 is a potent inhibitor of ROCK1 and ROCK2. It can indirectly inhibit ARHGAP40 by suppressing the Rho/ROCK pathway. | ||||||